Directive 2001/83/EC explained for EU human medicines teams
Directive 2001/83/EC is the EU code for human medicines. See what it covers, the key articles, and where the pharma reform stood in November 2026.
Directive 2001/83/EC explained
Directive 2001/83/EC is the EU Community code for medicinal products for human use and remains in force. It sets core rules for marketing authorisation, manufacturing and import, product information, distribution, advertising and pharmacovigilance. EUR-Lex lists 1 January 2025 as its current consolidated version (EUR-Lex).
The Directive was adopted on 6 November 2001 (EUR-Lex). The 2025 date marks the latest consolidation, not a new adoption. EUR-Lex treats a consolidated text as a documentation tool with no legal effect of its own. The authentic acts and amendments are the ones published in the Official Journal (consolidated text). In practice, cite "Directive 2001/83/EC as amended" and check the amending act itself when the exact wording matters. The original 2001 wording alone is not today's operative text.
What counts as a medicinal product
Article 1(2) defines a medicinal product by presentation or by function. Presentation means the product is presented as having properties for treating or preventing disease in human beings. Function means it is used in or administered to people to restore, correct or modify physiological functions through a pharmacological, immunological or metabolic action, or to make a medical diagnosis (consolidated text).
Article 2(1) applies the Directive to human medicines intended for the market in Member States and prepared industrially or by a method involving an industrial process. Article 2(2) covers borderline products. In cases of doubt, if a product may fit both the medicine definition and another EU regime, the Directive applies, after all the product's characteristics are taken into account. That is a case-by-case test. It does not make every food supplement or cosmetic a medicine. Article 2(3) extends specified manufacturing provisions to export-only medicines, intermediate products, active substances and excipients (consolidated text).
Article 3 lists exclusions. Examples include specified magistral and officinal preparations made in pharmacies, certain intermediate products, radionuclides in sealed sources, and blood and blood components. Industrially prepared plasma is not part of that blood exclusion. Excluded does not always mean unregulated. The hospital exemption for advanced therapy medicinal products is conditional, and it still requires national manufacturing authorisation and quality, traceability and pharmacovigilance requirements equivalent to those for authorised products (consolidated text).
Two more limits matter for commercial planning. Article 4 preserves national powers over pricing and reimbursement, so a marketing authorisation is not a reimbursement decision. Article 5 lets Member States make tightly conditioned arrangements for special needs and for public health threats (consolidated text).
Marketing authorisation and Regulation 726/2004
Article 6 is the starting rule. A medicine generally may not be placed on the market of a Member State without a marketing authorisation issued under the Directive or under Regulation (EC) No 726/2004, subject to the special provisions. Additional strengths, pharmaceutical forms, routes of administration and presentations, plus variations and extensions, belong to the same global marketing authorisation. This matters most when you calculate Article 10 protection periods (consolidated text).
Regulation 726/2004 sets up the centralised procedure. Its Articles 3 to 5 cover centralised scope, applications to the European Medicines Agency and the scientific opinions of its Committee for Medicinal Products for Human Use (CHMP). That opinion is a scientific assessment, not the authorisation decision itself. Article 6(1) of the Regulation imports the Directive's dossier rules, including Article 8(3), Article 10, Article 11 and Annex I (Regulation 726/2004). A centrally authorised medicine is still built on the Directive's dossier requirements.
The articles regulatory teams use most
Article 8(3) and the Annex I dossier
Article 8(3) lists what an application must contain. It includes quality and manufacturing information, the relevant pharmaceutical, nonclinical and clinical results, an environmental risk evaluation, information on the pharmacovigilance system, a risk management plan, and the proposed summary of product characteristics (SmPC), packaging and leaflet. Annex I organises the dossier into five CTD modules: EU administrative information, summaries, quality, nonclinical reports and clinical reports (consolidated text).
The evidence you need depends on the legal basis of the application. Not every application requires a newly generated full clinical programme (Annex I).
Article 10 generics and regulatory protection
Article 10 provides the 8+2(+1) framework. A qualifying generic applicant can rely on the reference product's data after eight years. The generic cannot be marketed until ten years have elapsed from the initial authorisation of the reference product. That period can extend to eleven years for a qualifying new indication that meets the statutory conditions, including significant clinical benefit in comparison with existing therapies (consolidated text).
These regulatory protection periods are separate from patents and supplementary protection certificates (Article 10).
Article 10(2)(b) defines a generic by its active-substance composition, pharmaceutical form and demonstrated bioequivalence, with statutory equivalences and possible waivers of bioavailability studies. Article 10(3) covers hybrid applications. Article 10(4) sets a separate route for similar biological products, so a biosimilar does not follow the same evidence route as an ordinary generic (consolidated text).
Product information in Articles 11, 23 and 54 to 63
Article 11 sets the content of the SmPC, including its clinical and pharmaceutical particulars. Article 23(3) requires the holder to keep product information up to date with current scientific knowledge, including the conclusions of relevant assessments. Articles 54 to 63 cover labelling and the package leaflet. Article 58 generally requires a leaflet unless all the required information is conveyed directly on the outer packaging or on the immediate packaging. Article 59 requires the leaflet to be in accordance with the SmPC and to reflect consultations with target patient groups (consolidated text). The SmPC and the leaflet are separate documents with separate rules.
Articles 40, 48 and 51 on manufacturing and the qualified person
Article 40 requires a manufacturing authorisation, including for imports from third countries and specified packaging operations, with a defined exception for pharmacy and retail preparation. Article 48 requires the authorisation holder to have at least one qualified person (QP) permanently and continuously available. Article 51 requires the QP to certify that each production batch satisfies the provisions of that article (consolidated text). The manufacturing QP is a different role from the qualified person responsible for pharmacovigilance (QPPV).
Pharmacovigilance under Title IX
Article 104 requires every marketing authorisation holder to run a pharmacovigilance system, with a QPPV, a pharmacovigilance system master file and ongoing monitoring of the benefit-risk balance. Article 107 covers the recording and reporting of suspected adverse reactions. Article 107b covers periodic safety update reports, with qualifications for certain product categories (consolidated text).
Is the EU pharmaceutical reform replacing Directive 2001/83/EC?
Yes, but not yet. As of 17 November 2026, both European Parliament procedure files for the pharmaceutical package read "Awaiting Parliament 2nd reading". They record a political agreement on 11 December 2025, the Council's first-reading position on 28 September 2026 and committee recommendations tabled on 13 November 2026. A plenary date of 23 November 2026 is listed as indicative (procedure 2023/0132(COD); procedure 2023/0131(COD)). Neither political agreement nor a committee recommendation completes the legislative process.
The Commission's communication COM(2026)526 final of 29 September 2026 describes what the package is meant to do. A new Directive would repeal Directives 2001/83/EC and 2009/35/EC. A companion Regulation would replace Regulation 726/2004 and the orphan and paediatric regulations. The communication describes agreed 24-month transposition and transition arrangements, with different timing for certain provisions (COM(2026)526). They belong to the agreed future framework. They are not deadlines already running.
Before you change a dossier, label or protection calculation, read the enacted text and its transitional provisions. Keep legislative adoption, Official Journal publication, entry into force and application separate.
A note for UK readers
Directive 2001/83/EC is not a uniform UK licensing code. The MHRA's Windsor Framework guidance, updated 31 January 2025, says new arrangements for product licensing, labelling and the Falsified Medicines Directive started on 1 January 2025. They include UK-wide licensing, common packs and the disapplication of FMD safety features for medicines marketed and supplied in Northern Ireland (MHRA). Check current MHRA guidance for UK products.
You can read RegAffairs AI's cited answer on what the EU human medicines directive covers and how the reform will change it.